LONDON, April 9, 2014 /PRNewswire/ --
On Tuesday, April 08, 2014, the
NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones
Industrial Average edged 0.06% higher to finish the day at
16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The
gains were broad based as seven out of ten sectors ended the
session in positive. The S&P 500 Health Care Sector Index
finished the day at 659.34, down 0.80%, and the same has fallen by
3.36% in the previous three trading sessions. Investor-Edge has
initiated coverage on the following equities: Valeant
Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC
(NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura
Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on
VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
http://www.investor-edge.com/937-register
Valeant Pharmaceuticals Intl. Inc.'s stock recorded a trading
volume of 5.18 million shares, as compared with its three months
average volume of 1.86 million shares. The stock ended the day at
$122.03, up 2.35%, trading between
$115.14 and $123.06. Valeant
Pharmaceuticals Intl. Inc.'s shares have plummeted 5.48% in the
previous three trading sessions, 13.68% in the last one month,
while the same has gained 3.94% on YTD basis. The company's stock
is trading above its 200-day moving average. Valeant
Pharmaceuticals Intl. Inc.'s 50-day moving average of $137.97 is above its 200-day moving average of
$113.69. Further, the stock has a
Relative Strength Index (RSI) of 28.12. Sign up today to read free
research on VRX at:
http://www.investor-edge.com/937-VRX-09Apr2014.pdf
On Tuesday, Alkermes PLC finished the session 2.38% higher at
$42.08. A total of 5.17 million
shares were traded, which is above its three months average volume
of 1.25 million shares. The stock fluctuated between $41.82 and $45.48 during the session. The
company's shares traded at a PE ratio of 154.14. Alkermes PLC's
stocks have declined 5.29% in the previous three trading sessions,
9.15% in the last one month, while the same has gained 3.49% on YTD
basis. The stock is trading above its 200-day moving average.
Alkermes PLC's 50-day moving average of $47.82 is above its 200-day moving average of
$38.68. Furthermore, the stock has an
RSI of 35.56. Sign up today to read free research on ALKS at:
http://www.investor-edge.com/937-ALKS-09Apr2014.pdf
Delcath Systems Inc.'s stock reported a trading volume of 1.44
million shares, as compared with its three months average volume of
4.84 million shares. The stock ended the day at $0.29, up 0.76%, after vacillating between
$0.28 and $0.31. Delcath Systems
Inc.'s shares have advanced 0.83% in the previous three trading
sessions and 14.71% on YTD basis, while the same has declined
11.36% in the last one month. The stock is trading below its 50-day
and 200-day moving averages of $0.31
and $0.34, respectively.
Additionally, the stock has an RSI of 43.97. Sign up today to read
free research on DCTH at:
http://www.investor-edge.com/937-DCTH-09Apr2014.pdf
Shares in Acura Pharmaceuticals Inc. gained 2.33%, to close the day
at $1.32. The stock recorded trading
volume of 0.23 million shares, as compared with its three months
average volume of 0.38 million shares. The stock oscillated between
$1.30 and $1.38 during the trading
session. Acura Pharmaceuticals Inc.'s shares have plummeted 8.97%
in the previous three trading sessions, 23.70% in the last one
month, and 20.96% on YTD basis. The stock is trading below its
50-day and 200-day moving averages of $1.70 and $1.73,
respectively. Furthermore, the company's shares have an RSI of
26.23. Sign up today to read free research on ACUR at:
http://www.investor-edge.com/937-ACUR-09Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Namrata
Maheshwari, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Namrata Maheshwari, CFA, has only
reviewed the information provided by Investor-edge in this article
or report according to the Procedures outlined by Investor-edge.
Investor-edge is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the
articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
Investor-Edge.com
SOURCE Investor-Edge